News

Press Releases

May 08, 2023

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 02, 2023

CRISPR Therapeutics to Participate Upcoming Investor Conferences

Apr 13, 2023

CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference

Apr 03, 2023

CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Presentations

Sep 22, 2022

CRISPR Therapeutics Corporate Presentation

Jun 21, 2022

Innovation Day Presentation

Jun 12, 2022

EHA 2022 (Exa-cel)

Jun 11, 2022

2022 EHA Oral Presentation (CTX130 COLBALT-LYM)

View All Presentations

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.